Wed, Sep 17, 2014, 1:57 AM EDT - U.S. Markets open in 7 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

  • lizdan_7 lizdan_7 Jan 24, 2013 11:56 AM Flag

    Ground floor opportunity, NO - YES

    As I have mentioned in other posts. I stated correct me if I am wrong but didn't the first patients injected report that they could read more letters on the eye chart. Also correct me if I am wrong that those patients could barley see anything before injection. Now we are injecting patients that have some sort of sight. ( you take it from here, how the price could react with any good news from the new patients. )
    I think am a holder and add more on dips.

    Always do as you feel,
    Not what you hear.

    Happy investing to all Sellers, and all Buyers

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If it drops temporarily -My buy order(for MORE shares) is in for .065!!!!

      Sentiment: Strong Buy

    • You have no published reports of the next 11 patients. And you are wrong about the first two. Only one had improved vision, the other had placebo affect that was questionable. the first 100K injection showed zero improvement. Many say Lancet was published way too early, only 10 weeks post injection for the first to patients. Nothing published since then, that shows results in detail of ANY patients (since Jan 2012),,,,the only way we know of the first 100K injection, is from Maurie herself stating no improvement in her blog postings.

      Is this ground floor? Not according to the deep pockets who normally would invest 100 million or so in this kind of cutting edge, life-enhancing science,,,,,they have not invested a dime in actc. Neither have the insiders.....if actc has 1/100th of the promise you allude to, you'd think the BOD and Lanza and Rabin would buy a few million shares for their extended families.....matters not that they receive a ton of free shares (dilution) at your expense,,,,,,,,why not buy more to gift them to extended family. Also, the BOD don't receive a "ton" of shares, like Lanza and Rabin,,,,,,,if actc went to a dollar today, BOD would not be filthy rich,,,,like Lanza and Rabin,,,,so why wouldn't Langer and other BOD members by millions more for seven or six cents,,,,,,,they would make a killing, IF they believed in management, and the science.

      Lastly, you can and do lose most of your investment, when you invest too early in a penny stock bio-tech (mostly thru dilution, but in this case, thru fraud on part of the management, see the SEC investigation, and the many lawsuits they have to pay out). ACTC trials are mid-way thru phase I. It will be years before phase III which is the critical stage for investors.

      • 2 Replies to karenlupa
      • No I do not have any published reports on the next 11 patients, (((( I actually do not remember saying I did )))
        All I said was that the next patients would have some sight. Below is a part on the News release.(((( Oh look Patients with BETTER vision will be eligible.))))

        Patients with better vision, a visual acuity of 20/100, will be eligible for enrollment in the remainder of the trials. By treating patients earlier in the course of the disease, the Company believes that the amended patient protocol will have a more significant impact on photoreceptor rescue and visual function

      • Really, then who posted this.
        Press Releases
        ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients

        Study in The Lancet Shows No Safety Concerns and Improved Vision in Patients with Macular Degeneration

        MARLBOROUGH, Mass. — Jan. 23, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT’s human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD). Results were reported for two patients, the first in each of the Phase 1/2 clinical trials. In addition to showing no adverse safety issues, structural evidence confirmed that the hESC-derived cells survived and continued to persist during the study period reported.

        ((((Both patients had measurable improvements in their vision that persisted for more than four months.))))

        (((( Measuring visual improvement in patients with very low vision is difficult, and no regulatory consensus exists regarding on how best to measure visual changes in these patients. As reported in The Lancet, the visual acuity of the Stargardt’s patient improved from hand motions only to 20/800 vision. Before treatment, the patient was unable to read any letter on the ETDRS visual acuity chart. However, by two weeks post-transplantation, she was able to start reading letters, which improved to five letters at one to three months in the treated eye. ))))

        My post below
        One had better than the other, yes. But as you can read in the first part of this news release ((((Both patients had measurable improvements in their vision that persisted for more than four months.))))

        Always do as you feel,
        Not what you hear.

        Happy investing to all Sellers and Buyers

 
ACTC
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.